7.50
+11.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Axe Compute
From its filings with the US Securities and Exchange Commission
Axe Compute is based in Miami, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AGPU. The SEC classifies its business as finance services. In the fiscal year to 31 December 2025, it reported revenue of $125,284 and a net loss of $233.1m. At that date it held total assets of $52.9m and shareholders' equity of $47.7m.
We embarked upon this direction because the global compute market represents a significant and rapidly growing commercial opportunity. According to Research and Markets (2026), the global compute market is estimated to be valued at over $1 trillion in 2026, with a compound annual growth rate of approximately 9.9%, and is expected to nearly double in value by 2032. When focused specifically on AI-related computing services, many forecasters estimate growth rates exceeding 30% annually, with the AI compute market anticipated to reach a total value in excess of $1 trillion by 2034 (Cognitive Market Research; Statifacts, 2025). McKinsey & Company estimated in 2025 that over 50% of all data center capacity was already dedicated to AI workloads, an amount they expect to grow by a factor of 3.5 times by 2030, and that approximately $6.7 trillion will be spent on data centers globally between 2025 and 2030, of which approximately 65.7% will be GPU-related. Gartner estimates worldwide AI spending will total $2.5 trillion in 2026 alone. Despite this unprecedented level of investment, demand continues to significantly outpace supply: as of early 2026, North American data center vacancy rates reached a record low of 1.6%, data center demand increased 24% in 2025, and average lead times for data center GPUs stand at 36 to 52 weeks (CBRE Investment Management, 2026).
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Dec 2009
- Employees
- 13
- Website
- precisiontherapeutics.com ↗
- Head office
- 91 43RD STREET, PITTSBURGH, PA, 15201
- Incorporated in
- DE
- Classification
- Finance Services
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Raymond VennareChairman of the Board, Chief Executive Officer, since 2021$525,000
- Mr. Joshua BlacherInterim Chief Financial Officer$453,940
- Mr. Chuck NuzumLead Independent Director$100,232
- Dr. Nancy Chung-WelchIndependent Director$76,668
- Dr. Daniel HandleyIndependent Director$55,977
- Dr. Matthew HawrylukIndependent Director$66,346
- Mr. Shawn MatthewsIndependent Director
- Dr. Veena RaoIndependent Director$78,258
- Mr. Gregory St. ClairIndependent Director$65,556
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Predictive Oncology, Inc. operates through subsidiaries like Helomics and Skyline Medical Inc.
- Helomics uses AI for personalized cancer therapies and CLIA-certified lab services.
- Skyline Medical Inc. markets the STREAMWAY System for automated medical fluid disposal.
Weaknesses
- The company has only 13 employees, which is low for its sector.
- Predictive Oncology, Inc. has a small workforce with 22 full-time employees.
- The company's IPO was in 2009, indicating limited recent growth.
Opportunities
- The Health Care sector offers growth potential for AI applications in oncology.
- Expanding the STREAMWAY System into international markets presents opportunities.
- Helomics' AI-driven therapies can attract new partnerships in Health Care.
Threats
- The Health Care sector faces regulatory challenges for AI applications.
- Competition in the Health Care sector may increase with new entrants.
- The company's small size could limit its ability to compete with larger firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.